Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Device issues

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Device issues. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-000220-14 Sponsor Protocol Number: TT 04 Start Date*: 2006-03-23
    Sponsor Name:TopoTarget A/S
    Full Title: A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation
    Medical condition: Accidental extravasation of anthracyclines
    Disease: Version SOC Term Classification Code Term Level
    7.1 10022062 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000326-24 Sponsor Protocol Number: INOT41 Start Date*: 2005-10-27
    Sponsor Name:INO Therapeutics
    Full Title: The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD) Implantation.
    Medical condition: Acute right ventricular failure.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10054933 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001265-28 Sponsor Protocol Number: ISD003-P144-08 Start Date*: 2008-06-17
    Sponsor Name:ISDIN
    Full Title: “Estudio abierto de extensión con P144 para la ampliación del tratamiento tópico de la fibrosis cutánea de pacientes con esclerosis sistémica previamente tratados en el ensayo ISD002-P144-07" “Op...
    Medical condition: "Fibrosis cutánea de pacientes con esclerosis sistémica" "Skin fibrosis in patients with systemic sclerosis"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003318-35 Sponsor Protocol Number: VX22-264-101 Start Date*: 2023-09-25
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004420-22 Sponsor Protocol Number: UCC-EMMIE Start Date*: 2015-03-06
    Sponsor Name:University College Cork
    Full Title: Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy
    Medical condition: Advanced Melanoma Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007127-40 Sponsor Protocol Number: D1443L00048 Start Date*: 2008-09-10
    Sponsor Name:Astra ZenecaGmbH
    Full Title: CARE II - Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre phase IV study
    Medical condition: Symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005003-41 Sponsor Protocol Number: 392MD/15/C Start Date*: Information not available in EudraCT
    Sponsor Name:Strakan Pharmaceuticals Ltd
    Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000410-18 Sponsor Protocol Number: 061002 Start Date*: 2011-05-05
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001201-10 Sponsor Protocol Number: FEN-PPA-401 Start Date*: 2004-07-26
    Sponsor Name:JANSSEN-CILAG
    Full Title: Comparison of transdermal fentanyl PCA and IV morphine PCA in the management of post-operative pain control.
    Medical condition: Treatment of moderate to severe post-operative pain in subjects who have undergone an elective major abdominal or orthopaedic surgical procedure.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10056350 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000200-23 Sponsor Protocol Number: 2017-BN-001 Start Date*: 2017-05-04
    Sponsor Name:UZ Brussel
    Full Title: Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma
    Medical condition: recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000985-12 Sponsor Protocol Number: AVA100468 Start Date*: 2004-08-03
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.
    Medical condition: Mild to moderate Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000029-28 Sponsor Protocol Number: P3-IMU-838-RMS-02 Start Date*: 2022-09-05
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000344-21 Sponsor Protocol Number: MP1032-CT05 Start Date*: 2021-07-21
    Sponsor Name:MetrioPharm AG
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD...
    Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021348-16 Sponsor Protocol Number: HGT-SAN-067 Start Date*: 2011-02-09
    Sponsor Name:Shire Human Genetic Therapies, Inc
    Full Title: An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
    Medical condition: Sanfilippo Syndrome Type A or Mucopolysaccharidosis (MPS IIIA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10056918 Sanfilippo's syndrome LLT
    19.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000729-70 Sponsor Protocol Number: MKI106209 Start Date*: 2006-07-11
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability, pharmacodynamics and steady-state pharmacokinetics of repeated doses of GW856553 in patients with C...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000694-39 Sponsor Protocol Number: SPL7013-018 Start Date*: 2014-10-22
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of SPL7013 Gel (VivaGel®) to prevent the recurrence of bacterial vaginosis
    Medical condition: recurrent bacterial vaginosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10004055 Bacterial vaginosis PT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-005010-22 Sponsor Protocol Number: LY03004/CT-EUR-101 Start Date*: 2019-04-26
    Sponsor Name:Nanjing Luye Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Open-Label, Cross-over Study to Assess the Relative Bioavailability of LY03004 and EU Risperdal® Consta® at 50 mg Following Multiple Intramuscular Injections in Stable Patients with S...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002204-27 Sponsor Protocol Number: GS030_CLIN_001 Start Date*: 2017-12-22
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa
    Medical condition: Retinitis Pigmentosa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000583-30 Sponsor Protocol Number: CBP-201-WW002 Start Date*: 2021-12-21
    Sponsor Name:Suzhou Connect Biopharmaceuticals Ltd.
    Full Title: A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation.
    Medical condition: Moderate to Severe Persistent Asthma with Type 2 Inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000028-36 Sponsor Protocol Number: P3-IMU-838-RMS-01 Start Date*: 2022-04-21
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:34:16 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA